Phase 1, open label, dose ranging clinical trial evaluating its second-generation oral norovirus vaccine
Latest Information Update: 29 Jun 2025
At a glance
- Drugs Norovirus vaccine (Primary)
- Indications Norovirus infections
- Focus Adverse reactions
Most Recent Events
- 11 Jun 2025 According to Vaxart media release, the company's senior management team will host a conference call to discuss the topline data from the norovirus Phase I trial today, beginning at 8:30 a.m. ET.
- 11 Jun 2025 According to Vaxart media release, the company intends to publish the complete results of this study in a peer-reviewed journal.
- 11 Jun 2025 Results presented in a Vaxart media release.